Compare · JNJ vs OSTX
JNJ vs OSTX
Side-by-side comparison of Johnson & Johnson (JNJ) and OS Therapies Incorporated (OSTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and OSTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $542.42B, about 5691.0x OSTX ($95.3M).
- Over the past year, JNJ is up 44.9% and OSTX is up 39.3% - JNJ leads by 5.6 points.
- JNJ has been more active in the news (11 items in the past 4 weeks vs 8 for OSTX).
- JNJ has more recent analyst coverage (25 ratings vs 1 for OSTX).
- Company
- Johnson & Johnson
- OS Therapies Incorporated
- Price
- $225.23-2.41%
- $2.15+8.06%
- Market cap
- $542.42B
- $95.3M
- 1M return
- -0.92%
- +31.60%
- 1Y return
- +44.93%
- +39.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2024
- News (4w)
- 11
- 8
- Recent ratings
- 25
- 1
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target
- Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Latest OSTX
- OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
- OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
- OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
- SEC Form 10-Q filed by OS Therapies Incorporated
- Amendment: SEC Form 5 filed by Romness Paul A.
- SEC Form NT 10-Q filed by OS Therapies Incorporated
- OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
- OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
- OS Therapies Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma